Bevirimat
Bevirimat Uses, Dosage, Side Effects, Food Interaction and all others data.
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein. Bevirimat is derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chinese herb. It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.
| Trade Name | Bevirimat |
| Generic | Bevirimat |
| Bevirimat Other Names | Bevirimat |
| Type | |
| Formula | C36H56O6 |
| Weight | Average: 584.8262 Monoisotopic: 584.407689524 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in HIV infection.
How Bevirimat works
Bevirimat has a novel mechanism of action, specifically inhibiting cleavage of spacer peptide 1 (SP1) from the C-terminus of capsid which results in defective core condensation. Specifically, bevirimat binds at the SP1/capsid junction, preventing cleavage by HIV protease.
Half Life
56.3 to 69.5 hours
Innovators Monograph
You find simplified version here Bevirimat
